Journal article
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study
- Abstract:
- Objectives: Eosinophilic bronchiectasis is defined by a blood eosinophil count (BEC) ≥300 cells/µL, but blood eosinophils imperfectly reflect airway eosinophilic inflammation. Here, we investigated the relationship between eosinophilic airway inflammation, blood eosinophils and clinical severity in bronchiectasis and explored the phenotype associated with eosinophilic bronchiectasis. Methods: Sputum from 180 patients with stable CT-confirmed bronchiectasis was utilised to investigate airway levels of eosinophil proteins (eosinophil peroxidase (EPX), eosinophil derived-neurotoxin (EDN), eosinophil cationic protein (ECP), major basic protein (MBP) and Galectin-10 (Gal-10)) using a novel stable isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. To profile eosinophilic bronchiectasis, a nested analysis of patients with BEC <150 cells/µL (n=52) and ≥300 cells/µL (n=49) was conducted. Results: Sputum concentrations of Gal-10, ECP and EDN were weakly but significantly associated with radiological severity, FEV1 and sputum culture positivity for Pseudomonas aeruginosa. Airway eosinophil protein concentrations did not associate with exacerbation frequency. Total eosinophil protein concentration moderately correlated with BECs (r=0.33 95% CI 0.14 to 0.49, p=0.0007). Nested analysis revealed increased sputum PCR-positivity for P. aeruginosa (26.7% vs 7.7%, p=0.033) and an increased frequency of patients showing signs of Aspergillus sensitisation (defined as Aspergillus-specific IgE titres >0.35 kUA/L, 24.5% vs 3.8%) in eosinophilic bronchiectasis. Sputum inflammatory biomarkers and clinical parameters did not differ between groups. Conclusions: LC-MS/MS can detect eosinophilic inflammation within bronchiectasis sputum. Weak associations between elevated airway eosinophil proteins, bronchiectasis severity and P. aeruginosa infection were observed. Direct measurement of eosinophilic airway inflammation provides additional information in addition to BECs. Eosinophilic bronchiectasis associated with P. aeruginosa infection and Aspergillus sensitisation.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.1MB, Terms of use)
-
- Publisher copy:
- 10.1136/thorax-2025-223305
Authors
+ GlaxoSmithKline
More from this funder
- Funder identifier:
- 10.13039/100004330
- Grant:
- no grant number
+ AstraZeneca UK
More from this funder
- Funder identifier:
- http://dx.doi.org/10.13039/100031315
- Grant:
- no award/grand number - independent research grant
+ Inhaled Antibiotic for Bronchiectasis and Cystic Fibrosis
More from this funder
- Grant:
- grant 115721
- Publisher:
- BMJ Publishing Group
- Journal:
- Thorax More from this journal
- Pages:
- thorax-2025-223305
- Article number:
- thorax-2025-223305
- Publication date:
- 2026-02-13
- Acceptance date:
- 2026-01-11
- DOI:
- EISSN:
-
1468-3296
- ISSN:
-
0040-6376
- Language:
-
English
- Keywords:
- Pubs id:
-
2379409
- Local pid:
-
pubs:2379409
- Source identifiers:
-
3792974
- Deposit date:
-
2026-02-24
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2026
If you are the owner of this record, you can report an update to it here: Report update to this record